Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216505 | 1.00 | TAAR1 (0.52) | TAAR1RIPK1AOC3TRPA1CACNA1F | |
| SCHEMBL13851912 | 1.00 | TAAR1 (0.52) | TAAR1RIPK1AOC3TRPA1CACNA1F | |
| SCHEMBL18355215 | 0.80 | TAAR1 (0.57) | TAAR1RIPK1AOC3CACNA1FCHRM2 | |
| SCHEMBL18676262 | 0.80 | RIPK1 (0.70) | TAAR1RIPK1AOC3TRPA1HRH1 | |
| SCHEMBL10414388 | 0.79 | TAAR1 (0.45) | TAAR1RIPK1AOC3TRPA1KDM4E | |
| SCHEMBL5664123 | 0.79 | RIPK1 (0.63) | TAAR1RIPK1AOC3TRPA1CACNA1F | |
| SCHEMBL9057427 | 0.78 | HTR2A (0.46) | TAAR1CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL11362801 | 0.77 | TAAR1 (0.52) | TAAR1RIPK1AOC3TRPA1CACNA1F | |
| SCHEMBL20427677 | 0.76 | RIPK1 (0.53) | TAAR1RIPK1AOC3TRPA1CACNA1F | |
| SCHEMBL21322418 | 0.76 | TAAR1 (0.56) | TAAR1RIPK1AOC3TRPA1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3816158-B1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS | KPC PHARMACEUTICALS INC (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020155595-A1 | AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR | 清华大学 | 2020-08-06 | — | — | WO | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2017051353-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051354-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017023905-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-1489064-B1 | Preparation of fluorinated acetophenones | SALTIGO GMBH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-7148384-B2 | Preparation of fluorinated acetophenones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050043559-A1 | Preparation of fluorinated acetophenones | LANXESS DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1489064-A1 | Preparation of fluorinated acetophenones | Bayer Chemicals AG (DE) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TAAR1 685/4885RIPK1 1464/4885AOC3 1363/4885 |
| US-20050043559-A1 | Preparation of fluorinated acetophenones | GNPAT, HNF4A, FAH | TAAR1 3536/4885RIPK1 4680/4885AOC3 1946/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TAAR1 685/4885RIPK1 1464/4885AOC3 1363/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TAAR1 652/4885RIPK1 1521/4885AOC3 1352/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TAAR1 685/4885RIPK1 1464/4885AOC3 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.